Submitted by QTR's Fringe Finance
Just yesterday even more ivermectin controversy started: this time around joint nonclinical research being done with the drug by Japanese company Kowa Co Ltd.
Except, instead of the “normal” ivermectin controversy - which consists of arguing over whether or not the drug is “horse paste” despite its discovery being nominated for a Nobel Prize for use in humans, it being including on the World Health Organization’s list of essential medicines and being dosed hundreds of millions of times to human beings by doctors - this week’s controversy was about how Kowa’s research was reported on Tuesday.
Reuters initially ran the headline:
“Japan's Kowa says ivermectin effective against Omicron in phase III trial”.
That headline was incorrect, and Reuters was forced to retract it. They re-ran the story with a title congruent with the facts:
Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says
Both ivermectin advocates and detractors claimed victory on the day.
Advocates claimed victory because it was yet another study - despite being a nonclinical joint study - that showed antiviral effects from the medicine in vitro. Ivermectin is already a well-known antiviral.
Ivermectin skeptics like the Washington Post claimed the article was “botched”, but still were forced to admit the truth: the “actual news” was that ivermectin was found to carry an “antiviral effect” against Omicron and other coronavirus variants in joint non-clinical research.
The facts as put forth in the corrected version of the Reuters article still seemed to be a net positive:
Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details
Kowa and Kitasato University appear to be in the midst of a clinical trial studying whether or not ivermectin is effective, though it was difficult to confirm the details due to a language barrier at the source of the information.
A translated version of Kowa’s Japanese PR seems to confirm that ivermectin is in the midst of a clinical trial for Covid. Included in the translated PR were the following lines:
It is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases.
In this clinical trial, the dosage and administration already approved as a therapeutic agent for parasitic infections
Although it is different, we are confirming its efficacy and safety in clinical trials.
Kowa confirmed the clinical effect of ivermectin on SARS-CoV-2 and was one of the first to the public.
But, let’s put aside the Kowa study for a second.
What most people don’t know is that this Japanese trial, whether successful or not - whether clinical or nonclinical - would only serve to supplement robust data already available about ivermectin’s effectiveness on Covid-19.
The website c19ivermectin.com keeps a running tally of such studies, and aggregates the data as it comes in.
The website keeps a chronological log of studies, news, theories, of all types of information available about ivermectin that can be aggregated, including meta analyses, dating back to April of 2020. At most recent update, it includes 147 studies, 96 peer reviewed, 77 with results comparing treatment and control groups. (It currently includes the Kowa writeup, but has yet to correct the Reuters headline as of the time of this writing.)
The website also notes that Ivermectin has been officially adopted for early treatment in all or part of 22...(READ THIS FULL ARTICLE HERE).
Today’s blog post has been published without a paywall because I believe the content to be far too important to deny to anyone. However, if you have the means and would like to support my work by subscribing, I’d be happy to offer you 22% off for 2022: Get 22% off forever